Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 331

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1C
Chunk 331
---
242,137 
    $72  
    $2,045,206  
    $(7,916,337) 
    $(5,871,058)

See accompanying notes to consolidated financial
statements.

 F-6 

Mosaic ImmunoEngineering, Inc.

Consolidated Statements of Cash Flows

    Year Ended December 31, 

    2024  
    2023 
  
    Operating activities: 

    Net loss 
    $(921,983) 
    $(1,008,235)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Share-based compensation 
     4,867  
     21,935 
  
    Gain on redemption of preferred stock of Holocom 
     –  
     (433,000)
  
    Change in fair value of derivative liability 
     –  
     (46,700)
  
    Non-cash interest on convertible notes 
     73,533  
     73,333 
  
    Accretion to redemption value on convertible notes 
     1,446  
     15,842 
  
    Changes in operating assets and liabilities: 

    Prepaid expenses and other current assets 
     (3,237) 
     17,277 
  
    Accounts payable 
     16,387  
     (14,986)
  
    Accrued compensation 
     582,741  
     785,779 
  
    Accrued consulting 
     –  
     34,333 
  
    Accrued expenses and other 
     5,087  
     56,955 
  
    Net cash used in operating activities 
     (241,159) 
     (497,467)

    Investing activities: 

    Proceeds from redemption of preferred stock of Holocom 
     –  
     433,000 
  
    Net cash provided by investing activities 
     –  
     433,000 

    Financing activities: 

    Proceeds from the issuance of loans payable 
     270,000  
     – 
  
    Payments on loan payables 
     (70,000) 
     – 
  
    Net cash provided by financing activities 
     200,000  
     – 

    Net change in cash and cash equivalents 
     (41,